Who are DE-104 ophthalmic solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azelaic Acid Cream, Dapsone gel, 5%, Anelazol Sodium Enteric-coated Tablets, intraperitoneal nebulisation of magnesium sulphate, andrographolide sulfonate simulation, Topical Coal tar.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/de-104-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

DE-104 ophthalmic solution — Competitive Intelligence Brief

DE-104 ophthalmic solution (DE-104 ophthalmic solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-inflammatory agent. Area: Ophthalmology.

phase 2 Anti-inflammatory agent Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

DE-104 ophthalmic solution (DE-104 ophthalmic solution) — Santen Pharmaceutical Co., Ltd.. DE-104 ophthalmic solution is an anti-inflammatory agent that reduces inflammation in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DE-104 ophthalmic solution TARGET	DE-104 ophthalmic solution	Santen Pharmaceutical Co., Ltd.	phase 2	Anti-inflammatory agent
Azelaic Acid Cream	Azelaic Acid Cream	LEO Pharma	marketed	Topical antimicrobial and anti-inflammatory agent
Dapsone gel, 5%	Dapsone gel, 5%	Vanderbilt University Medical Center	marketed	Sulfone antimicrobial and anti-inflammatory agent	Dihydrofolate reductase; neutrophil function modulation
Anelazol Sodium Enteric-coated Tablets	Anelazol Sodium Enteric-coated Tablets	Xuanzhu Biopharmaceutical Co., Ltd.	marketed	Leukotriene inhibitor / Anti-inflammatory agent	Leukotriene synthesis pathway
intraperitoneal nebulisation of magnesium sulphate	intraperitoneal nebulisation of magnesium sulphate	B.P. Koirala Institute of Health Sciences	marketed	Mineral supplement / Anti-inflammatory agent	NMDA receptor (indirect antagonism); local anti-inflammatory pathways
andrographolide sulfonate simulation	andrographolide sulfonate simulation	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	marketed	Natural product derivative; anti-inflammatory agent
Topical Coal tar	Topical Coal tar	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	Keratolytic and anti-inflammatory agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-inflammatory agent class)

Santen Pharmaceutical Co., Ltd. · 2 drugs in this class
Santen Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DE-104 ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/de-104-ophthalmic-solution. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab